Type Whole antibody Target IL17A AHFS/Drugs.com cosentyx | Trade names Cosentyx | |
Pregnancycategory US: B (No risk in non-human studies) | ||
Secukinumab, trade name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is manufactured by Novartis Pharma AG for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17, severely inhibiting its functioning. On January 21, 2015, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis. On January 15, 2016, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with ankylosing spondylitis, and psoriatic arthritis.
Although the drug was originally intended to treat rheumatoid arthritis, phase II clinical trials for this condition yielded disappointing results.
A phase II clinical trial for multiple sclerosis completed in 2014 as it had exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Results of this trial have not yet been reported as of April 2015
Standard protocol
Patients begin treatment with five booster shots of 300 mg subcutaneous each one taken a week apart, followed by regular injections once a month thereafter for 5 months.